Killer dendritic cells: IKDC and the others.

Bonmort M, Dalod M, Mignot G, Ullrich E, Chaput N, Zitvogel L.
Curr Opin Immunol. 2008 Oct;20(5):558-65. Epub 2008 Jun 12.

Tumors can regress as a result of invading myeloid and lymphoid cells that act in concert. Although the myeloid cells are widely recognized as antigen presenters and lymphoid cells as classical effectors, recent evidence revealed the capacity of dendritic cells (DC) to kill tumor cells. The functional concept of 'natural killer (NK) myeloid DC' is supported by mouse and human in vitro data that may be clinically relevant because human killer DC can contribute to tumor shrinking during topical therapy with toll-like receptor (TLR) agonists. Whether tumor killing by DC is a 'catalyzing' step for efficient crosspresentation and/or a promoting step for an immunogenic cell death pathway remains an open question. We also discuss how interferon-producing killer DC (IKDC) may participate in the control of tumor progression.

URL: http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VS1-4SRC3V7-1&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=57a132686928f2d2115b6d59ce9d5c40

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/18554881

created over 15 years ago (17 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]